Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to its product development and strategy team. In a statement on Thursday morning (Australian time), the company said Dr Emilio Emini, Dr Nathalie Garcon, and Professor Paul Young will join Vaxxas as consultants to provide regulatory…
The Coalition for Epidemic Preparedness Innovations (CEPI) has approved progression of a $US 4.8 million ($7.2 million) program involving Vaxxas — a Brisbane-based, clinical-stage company developing a needle vaccine delivery platform — and an mRNA Japanese encephalitis vaccine (JEV) from SK bioscience. According to a statement from Vaxxas on Thursday, the program is to develop…
Optiscan Imaging advances veterinary medtech Confocal microscopy manufacturer Optiscan Imaging has signed a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine. The agreement follows a MOU with the university, and is a step in expanding the clinical applications of Optiscan’s confocal endomicroscope imaging system in veterinary medicine. The initial focus of…
Needle free biotechnology company Vaxxas has announced that the United States National Institutes of Health (NIH) has granted the company a licence to a vaccine antigen candidate (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV). RSV is a common contagious virus affecting the lungs and breathing passages which causes an estimated…
Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…
Needle-free vaccine delivery company Vaxxas has announced it was awarded $5.4 million from charitable foundation Wellcome for initial studies and a Phase I clinical trial of a potential second-generation typhoid vaccine delivered using Vaxxas’ technology. In a statement on Thursday, the Brisbane-based clinical-stage company said the project is expected to be completed within two years,…
